TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03375775
Drug: Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to standardized clinical protocol
Study: NCT00657891
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Injection
Study: NCT01305538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00385645
Drug: Combivir+Reyataz
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00978029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual tablet, once daily
Study: NCT03615196
Drug: USB005 Ophthalmic Solution Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A clinical placebo formulated with the same excipients and packaged in the same container closure system as the active product, USB005 (aclerastide) Ophthalmic Solution.
Study: NCT04422860
Drug: Proflourid Varnish,VOCO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% NaF varnish
Study: NCT04422860
Drug: MI Varnish,GC Japan Inc.
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPP-ACP with fluoride based varnish
Study: NCT00899054
Drug: P276-00
Approvals — FDA: no, EMA: no, PMDA: no
Description: P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
Study: NCT00767091
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal patch of placebo
Study: NCT03016325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT00731575
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
Study: NCT04572477
Drug: [18F]AV-45
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-18 AV45 PET Imaging
Study: NCT03424707
Drug: DW340(pelubiprofen/eperisone)
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DW340
Study: NCT03424707
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT00131391
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily . 52 week treatment period.
Study: NCT01352091
Drug: Zoladex+AI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
Study: NCT03969121
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
Study: NCT00812058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
Study: NCT00083031
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00083031
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00886600
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
Study: NCT01708642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative isotonic saline infusion as placebo for adrenaline.
Study: NCT01696240
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
Study: NCT00586209
Drug: L-Glutamine
Normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (\>66.7 kg)
Study: NCT00586209
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
Study: NCT02343172
Drug: HDM201
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02343172
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01179009
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline (i.e. placebo ketamine)
Study: NCT04229225
Drug: UBX0101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug intra-articular (IA) injection
Study: NCT00503477
Drug: AZD2171
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04460547
Drug: Convalescent Plasma Transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent Plasma Transfusion to COVID-19 infected patients.
Study: NCT00092846
Drug: MK0803, lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02398591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
Study: NCT04460547
Drug: DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS181 administration to COVID-19 infected patients.
Study: NCT03358888
Drug: Multi-modal with as needed opioids
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal with as needed oxycodone and tramadol provided for break-through pain
Study: NCT03358888
Drug: Multi-modal with one week of opioids offered
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
Study: NCT03358888
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
Study: NCT03972683
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.
Study: NCT01748539
Drug: KHK4827
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01748539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03563378
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered normal saline for intraoperative fluid management.
Study: NCT01075555
Drug: pravastatin sodium
Normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02940509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
Study: NCT00859105
Drug: Adara 5% Cream US
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
Study: NCT00859105
Drug: Adara 5% Cream Canada
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
Study: NCT01660945
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01175135
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet/capsule every 12 hours for 28 days
Study: NCT00222625
Drug: FFP or aPCC+ vit K in AO treated patients
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01061814
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
Study: NCT03060538
Drug: BFKB8488A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously starting on Day 1 and according to dosing schedule.
Study: NCT02228460
Drug: GZ/SAR402671
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Capsule; Route of administration: Oral
Study: NCT04101461
Drug: Iron
Normalized name: Iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PharaFerro27; Devart Lab Company, Egypt
Study: NCT03859102
Drug: Intravenous Paracetamol intra-operatively
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of Paracetamol intra-operatively, 1gram intravenous infusion.
Study: NCT03859102
Drug: Infiltration of surgical wounds with local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.
Study: NCT03488147
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: resembling esomeprazole tablet
Study: NCT03187106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo representing standard of care
Study: NCT00841698
Drug: Paxil®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg Film-Coated Tablet
Study: NCT04622956
Drug: Methotrexate Injectable Solution
Normalized name: methotrexate Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1:~* Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9\*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~* Level 0 \[Starting Dose\]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~* Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~* Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial
Study: NCT01100437
Drug: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
Study: NCT01100437
Drug: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
Study: NCT04499443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
Study: NCT01964014
Drug: advagrf
Approvals — FDA: no, EMA: no, PMDA: no
Description: All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat.
Study: NCT02258828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo
Study: NCT05363059
Drug: Hypoglycemic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug
Study: NCT01003275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two soft gels by mouth daily for 8 weeks
Study: NCT00894556
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Rizatriptan
Study: NCT02289950
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered intravenously (IV) weekly
Study: NCT00426621
Drug: Diclofenac Sodium Gel
Normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 grams per knee, 4 times per day, for 12 weeks
Study: NCT00426621
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 grams per knee, 4 times per day, for 12 weeks
Study: NCT03932058
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
Study: NCT02528903
Drug: MHAB5553A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous administration, at various doses, depending on the cohort
Study: NCT02528903
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose
Study: NCT02175602
Drug: DCV 3DAA FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
Study: NCT01043952
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
Study: NCT00239382
Drug: Meloxicam ampoule
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00239382
Drug: Meloxicam tablet
Normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03352362
Drug: ibuprofen (caldolor 10 mg / kg)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
Study: NCT03352362
Drug: ibuprofen + propacetamol
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
Study: NCT01067833
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, x28 days
Study: NCT01218867
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
Study: NCT04890418
Drug: Ketalar, 5 mg/mL Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.
Study: NCT03829657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, QD
Study: NCT04194528
Drug: Oxycodone/acetaminophen 5/325 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
Study: NCT00271817
Drug: Comparator: ezetimibe/simvastatin + niacin (ER)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
Study: NCT00271817
Drug: Comparator: ezetimibe (+) simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.
Study: NCT00271817
Drug: Comparator: ezetimibe/simvastatin and niacin (ER)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks
Study: NCT00271817
Drug: Comparator: ezetimibe and simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
Study: NCT01278095
Drug: GLPG0555 solid dispersion
Approvals — FDA: no, EMA: no, PMDA: no
Description: solid dispersion capsules, 50 mg, single dose
Study: NCT01278095
Drug: GLPG0555 nanosuspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanosuspension, 50 mg, single dose
Study: NCT00834405
Drug: ARAVA® 20 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 20 mg, single-dose non-fasting
Study: NCT03919526
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300mg/m2/d
Study: NCT01632462
Drug: VSL#3
Normalized name: VSL#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks.
Study: NCT00871247
Drug: Proscar® 5 mg Tablet, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
Study: NCT03216473
Drug: Neuronox
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clostridium Botulinum Toxin A 100 U
Study: NCT01425008
Drug: MLN2480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
Study: NCT03503318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to TV-46000 will be administered per schedule specified in the arm.
Study: NCT00954590
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally three times daily
Study: NCT00916253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo.
Study: NCT00247897
Drug: Skin antisepsis
Normalized name: Skin antisepsis, oral cleansing, nasal antisepsis KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description
Study: NCT04342221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT01148537
Drug: Matching placebo transdermal patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch to match BTDS 5, 10, 20, and 2 \* 20.
Study: NCT03306732
Drug: Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline
Normalized name: NS-2
DrugBank: Reproxalap (DB16688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)
Study: NCT01353027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT03500900
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute administration of placebo tablet
Study: NCT02403947
Drug: Suspension media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection suspension media
Study: NCT01974544
Drug: Best medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.